TARA's in vitro human cardiac models replicate drug responses similar to those observed in humans, supporting their use as a robust platform for new medicines evaluation. The models' ability to reproduce diverse mechanisms of action showcases their applicability for cardiac drug discovery and development.
The Quantum-Si ecosystem enables sensitive and accurate research tools and diagnostics through digital proteomics, transforming the study of proteins on a large scale. The company's platform offers a complete solution for sample preparation, sequencing, and data analysis, reducing costs and increasing accessibility.
The study highlights the efficacy of Bluestar Genomics' 5-hmC signal detection technology for detecting breast, lung, pancreatic, and prostate cancer from a single blood draw. The technology demonstrated high performance in classifying samples with high Area Under the Curve measures.
TARA Biosystems' human heart-on-a-chip technology shows promise in predicting preclinical systolic and diastolic in vivo observations for novel cardiac drug MYK-491. The platform uses human induced pluripotent stem cells to create physiologically relevant cardiac tissues.
Researchers replicated human-like drug responses in TARA's engineered heart-on-a-chip system, predicting cardiac safety and efficacy. The study validated the platform's ability to model different heart diseases and measure contractile force of Cardiotype tissues.
Research studies using liquid biopsy and ddPCR technology found that mutant BRAF ctDNA levels can predict treatment efficacy in advanced melanoma patients, while ctDNA may not reliably detect brain metastases. Meanwhile, chimeric cell-free DNA tracked tumor recurrence in hepatocellular carcinoma patients.
Researchers presented studies on the clinical utility of liquid biopsy powered by ddPCR technology to measure blood-based tumor biomarkers in a reproducible way. Studies demonstrated correlations between ctDNA mutations and response to abemaciclib in breast cancer patients and found potential as a predictor for surgery success in malig...
A recent study published online demonstrated that Droplet Digital PCR technology can detect and quantify rare mutations in the TERT promoter region with high sensitivity. The assays detected the mutation in 78% of samples and yielded no false positives, showing its potential as a biomarker for diagnosing and monitoring patients.
Researchers used Bio-Rad's Droplet Digital PCR technology to identify potential epigenetic biomarkers for lung cancer recurrence and detect HPV cfDNA in cervical cancer patients. The studies found associations between biomarker levels and treatment outcomes, indicating the clinical utility of ddPCR technology.
The QXDx BCR-ABL %IS Kit uses Droplet Digital PCR technology to detect deep molecular response values with high reproducibility and precision. This allows for more confident disease management decisions in patients with chronic myeloid leukemia.
Researchers showcased Droplet Digital PCR's use in detecting rare mutations, including stem cell integrity and cancer-related de novo mutations. The technology also enabled the non-invasive detection of transplant rejection through cell-free DNA measurement, offering a promising alternative to invasive methods.
Researchers used Bio-Rad's Droplet Digital PCR to detect patient response to immunotherapies, identifying pseudoprogression. A biomarker detected by ddPCR indicates how well patients with non-small cell lung cancer respond to treatment, guiding toxic treatments only when necessary.
A multicenter study of 21 laboratories demonstrated digital PCR's high reproducibility in quantifying cancer mutations across different locations. The method showed greater reproducibility and reduced variability compared to real-time quantitative PCR.
Researchers presented advancements in Droplet Digital PCR for detecting somatic cancer mutations, including novel methods for differentiating between mutant alleles and quantifying biomarker copy numbers. Single-cell sequencing was also showcased for understanding human pluripotent stem cell population heterogeneity.
A study published in the Journal of Virological Methods found that Bio-Rad's Droplet Digital PCR (ddPCR) technology significantly increases the sensitivity and precision of mutation abundance quantification when compared to RT-qPCR. This makes it an ideal tool for detecting viral RNA mutations in clinical samples.
Researchers presented various applications of Bio-Rad's Droplet Digital PCR, including copy number determination, genome editing, and liquid biopsy. The technology demonstrated precision, reproducibility, and sensitivity in detecting complex genomic rearrangements and biomarker levels.
A study has identified a novel microRNA, miR-181a-5p, as a potential diagnostic breast cancer biomarker in the blood. The use of Droplet Digital PCR technology enabled the accurate quantification of this miRNA, which showed significant downregulation in the serum of patients with breast cancer.
A new method using Droplet Digital PCR Technology enables rapid determination of chromosomal phase of allelic markers hundreds of kilobases apart, providing insights into disease cause and severity. This technology overcomes challenges of current phasing methods, allowing researchers to quickly and affordably determine haplotype data.
Researchers used next-generation sequencing and Bio-Rad's Droplet Digital PCR technology to accurately count diverse copy number states of multiallelic copy number variations (mCNVs) in humans. The study found that mCNVs are responsible for nearly 90% of observed differences in gene copy number, contributing substantially to gene expre...
The technology is being showcased at the AACR Annual Meeting, where researchers are highlighting its potential for cancer research. Studies have demonstrated the use of ddPCR to track treatment response in melanoma patients and quantify mutant genes in plasma and serum.
Researchers at Fred Hutchinson Cancer Research Center used Droplet Digital PCR to quantify tumor-infiltrating T-lymphocytes (TILs), a subpopulation of immune cells that improve cancer survival. Higher TIL levels correlate positively with patient survival, suggesting an active role in suppressing tumor formation. The study paves the way...
Researchers used Bio-Rad's Droplet Digital PCR to obtain promising results in new copy number variation studies, showcasing its precision, reproducibility, and sensitivity. The technology has already resulted in nearly 50 peer-reviewed publications.
Researchers using Bio-Rad's Droplet Digital PCR systems highlighted the technology's potential to transform clinical applications. Studies demonstrated increased precision, accuracy, and sensitivity compared to real-time PCR methods, particularly in detecting rare cancer mutations and genomic alterations.
Researchers have developed a new blood test that can detect cancer metastasis in dogs by analyzing cell-free DNA in blood plasma. The test has shown promising results in detecting minimal residual disease and tracking tumor progression, with potential implications for human cancer treatment.
Researchers have developed a new assay called Digital Deletion Detection (3D) that accurately analyzes extremely rare mitochondrial DNA deletions associated with aging. The method uses Droplet Digital PCR technology to detect these deletions, which are often missed by conventional methods.
A study published in Nature Methods demonstrates Droplet Digital PCR's ability to precisely and reproducibly quantify microRNA in plasma and serum across different days. This technology can improve the development of miRNA-based blood-based biomarkers, such as those for cancer diagnosis.
Researchers have developed a fast and affordable blood test to detect early signs of organ rejection in transplant patients. The new test uses Droplet Digital PCR technology, which can identify graft-derived cell-free DNA released into the bloodstream by dying cells from the transplanted organ.
A study found that Droplet Digital PCR can accurately quantify and determine the size distribution of target DNA in a single reaction well, avoiding drawbacks of other methods. This method offers precise quantification and detailed size distribution analysis, enabling efficient library preparation for next-generation sequencing.
A study identified a potential biomarker for Alzheimer's disease in cerebral spinal fluid, suggesting the condition may be detectable a decade before symptoms appear. Researchers hope to find treatments that can prevent or slow the progression of the disease.
A PLOS ONE study has confirmed that Droplet Digital PCR (ddPCR) technology is suitable for routine analysis of genetically modified organisms (GMOs) in food, feed, and seeds. The study found that ddPCR is more accurate and reliable than real-time quantitative PCR (qPCR) for quantifying GMOs, especially at low levels.
A gene-based test accurately identified a subgroup of very high-risk smokers who accounted for over 50% of all lung cancer cases. The study found that targeting these individuals with low-dose CT screening could significantly improve the number of early-stage lung cancer cases found, making screening more cost-effective.
A gene-based test for lung cancer risk assessment motivates smokers to quit or cut down, according to a clinical study. The test, Respiragene, resulted in 32% of smokers quitting altogether and another 48% reducing their cigarette intake.
A new approach to smoking cessation uses individualized risk assessments to motivate smokers to quit. Studies show that tests like Respiragene improve quit rates by providing smokers with personalized information about their risk of lung cancer and other smoking-related diseases.